Compare ACI & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACI | DVA |
|---|---|---|
| Founded | 1860 | 1994 |
| Country | United States | United States |
| Employees | 270000 | N/A |
| Industry | Food Chains | Misc Health and Biotechnology Services |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3B | 10.1B |
| IPO Year | 2015 | 2002 |
| Metric | ACI | DVA |
|---|---|---|
| Price | $17.30 | $151.37 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 14 | 4 |
| Target Price | $22.29 | ★ $156.75 |
| AVG Volume (30 Days) | ★ 5.2M | 829.4K |
| Earning Date | 04-07-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.38% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 1.25 | ★ 9.84 |
| Revenue | ★ $80,390,900,000.00 | $13,643,069,000.00 |
| Revenue This Year | $4.69 | $3.80 |
| Revenue Next Year | N/A | $3.04 |
| P/E Ratio | ★ $14.20 | $15.35 |
| Revenue Growth | 1.46 | ★ 6.46 |
| 52 Week Low | $15.80 | $101.00 |
| 52 Week High | $23.20 | $159.42 |
| Indicator | ACI | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 46.16 | 62.03 |
| Support Level | $16.91 | $146.00 |
| Resistance Level | $17.74 | $159.42 |
| Average True Range (ATR) | 0.50 | 4.29 |
| MACD | -0.10 | -1.25 |
| Stochastic Oscillator | 26.01 | 43.33 |
Albertsons is the second-largest supermarket operator in the United States with about 2,300 stores across a variety of banners. Around 80% of the firm's sales comes from nonperishable and fresh food, of which 26% comes from its portfolio of private brands. The company operates fuel centers at about 20% of its store locations and pharmacies at 75%. Albertsons went public in 2020 following years of ownership under private equity firm Cerberus Capital Management, which still owns about a fourth of the outstanding shares.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.